CABALETTA BIO, INC. Proceeds from Stock Options Exercised
CABALETTA BIO, INC. (CABA) reported Proceeds from Stock Options Exercised of $66.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2026-08-13
- CABALETTA BIO, INC. proceeds from stock options exercised for the quarter ending 2026-06-30 was $34.00K.
- CABALETTA BIO, INC. proceeds from stock options exercised for the quarter ending 2026-03-31 was $32.00K.
- CABALETTA BIO, INC. proceeds from stock options exercised for the quarter ending 2025-12-31 was $0.00.
- CABALETTA BIO, INC. proceeds from stock options exercised for the quarter ending 2025-09-30 was $14.00K, a 80.28% decline year-over-year.
- CABALETTA BIO, INC. proceeds from stock options exercised for fiscal 2025 was $14.00K, a 99.02% decline from fiscal 2024.
- CABALETTA BIO, INC. proceeds from stock options exercised for fiscal 2024 was $1.43M, a 38.39% decline from fiscal 2023.
- CABALETTA BIO, INC. proceeds from stock options exercised for fiscal 2023 was $2.32M, a 4450.98% increase from fiscal 2022.
- CABALETTA BIO, INC. proceeds from stock options exercised for fiscal 2022 was $51.00K, a 91.19% decline from fiscal 2021.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $34.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $66.00K 10-Q · filed 2026-08-13 | $66.00K derived: sum of 3 quarters · filed 2026-08-13 | $80.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $32.00K 10-Q · filed 2026-05-14 | $32.00K derived: sum of 2 quarters · filed 2026-05-14 | $46.00K derived: sum of 3 quarters · filed 2026-05-14 | $46.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $14.00K derived: sum of 2 quarters · filed 2026-03-23 | $14.00K derived: sum of 3 quarters · filed 2026-08-13 | $14.00K 10-K · filed 2026-03-23 |
| 2025-09-30 | $14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $14.00K derived: sum of 2 quarters · filed 2026-08-13 | $14.00K 10-Q · filed 2025-11-10 | $14.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-08-13 | $71.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | $0.00 derived: sum of 2 quarters · filed 2026-05-14 | $71.00K derived: sum of 3 quarters · filed 2026-05-14 | $321.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $71.00K derived: sum of 2 quarters · filed 2026-03-23 | $321.00K derived: sum of 3 quarters · filed 2026-03-23 | $1.43M 10-K · filed 2026-03-23 |
| 2024-09-30 | $71.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $321.00K derived: sum of 2 quarters · filed 2025-11-10 | $1.43M 10-Q · filed 2025-11-10 | $2.66M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $250.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.36M 10-Q · filed 2025-08-07 | $2.59M derived: sum of 3 quarters · filed 2025-08-07 | $2.83M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.11M 10-Q · filed 2025-05-15 | $2.34M derived: sum of 2 quarters · filed 2025-05-15 | $2.58M derived: sum of 3 quarters · filed 2025-05-15 | $2.97M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.47M derived: sum of 2 quarters · filed 2025-03-31 | $1.86M derived: sum of 3 quarters · filed 2025-03-31 | $2.32M 10-K · filed 2025-03-31 |
| 2023-09-30 | $239.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $629.00K derived: sum of 2 quarters · filed 2024-11-14 | $1.09M 10-Q · filed 2024-11-14 | $1.09M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $390.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $848.00K 10-Q · filed 2024-08-08 | $848.00K derived: sum of 3 quarters · filed 2024-08-08 | $848.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $458.00K 10-Q · filed 2024-05-15 | $458.00K derived: sum of 2 quarters · filed 2024-05-15 | $458.00K derived: sum of 3 quarters · filed 2024-05-15 | $458.00K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $0.00 derived: sum of 2 quarters · filed 2024-03-21 | $0.00 derived: sum of 3 quarters · filed 2024-03-21 | $51.00K 10-K · filed 2024-03-21 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $51.00K 10-Q · filed 2023-11-09 | $111.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $51.00K 10-Q · filed 2023-08-10 | $111.00K derived: sum of 3 quarters · filed 2023-08-10 | $570.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $51.00K 10-Q · filed 2023-05-11 | $111.00K derived: sum of 2 quarters · filed 2023-05-11 | $570.00K derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $60.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $519.00K derived: sum of 2 quarters · filed 2023-03-16 | $579.00K 10-K · filed 2023-03-16 | |
| 2021-09-30 | $459.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $519.00K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $60.00K 10-Q · filed 2022-08-11 | |||
| 2020-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $139.00K 10-K · filed 2022-03-17 | ||
| 2020-09-30 | $135.00K 10-Q · filed 2021-11-01 | |||
| 2019-12-31 | $6.00K 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |